Intellia Therapeutics Claimed Company
Intellia Therapeutics is a leading genome editing company focused on developing proprietary, curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course, and through improved cell therapies that can treat cancer and immunological diseases, or can replace patients’ diseased cells. The combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. read more
HR or Marketing? Claim Your Free Employer Account
Intellia Therapeutics CEO & Leadership Team Ratings
John Leonard and the Intellia Therapeutics leadership team are scored an "A-" by 10 employees placing it in the Top 15% of companies sized 201-500 Employees on Comparably. The Leadership Score of 79/100 is based on 41 ratings; it combines employee feedback on their CEO (86/100), Manager (79/100), and Executive Team (73/100).
John Leonard Intellia Therapeutics CEO Rating
Top 5% Compared to other companies of similar size in BostonA+
86 / 100
John Leonard the CEO of Intellia Therapeutics received an average score of 86 from Intellia Therapeutics employees.Intellia Therapeutics Manager Rating
Top 20% Compared to other companies of similar size in BostonB+
79 / 100
Intellia Therapeutics Executive Team Rating
Top 30% Compared to other companies of similar size in BostonB
73 / 100
×